Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR NP_005219.2:p.L858R”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Early research (Phase 1)Looking for participantsNCT06955988
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT01532089
What this trial is testing

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Who this might be right for
EGFR Exon 19 Deletion MutationEGFR NP_005219.2:p.L858RLung Non-Squamous Non-Small Cell Carcinoma+1 more
Academic and Community Cancer Research United 88
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Testing effectiveness (Phase 2)UnknownNCT04988607
What this trial is testing

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 90
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970
What this trial is testing

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Who this might be right for
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
Daiichi Sankyo 586
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782
What this trial is testing

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 278
Not applicableLooking for participantsNCT06053099
What this trial is testing

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Who this might be right for
Non Small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique 300
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT05263947
What this trial is testing

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungBevacizumabEGF-R Positive Non-Small Cell Lung Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 35